Year-end Sale % OFF 
Abstract
In the phase Ib/II EVICT trial, the combination of vemurafenib and erlotinib demonstrated promising efficacy with response rates of 32% (10/31; 16% -5/31 confirmed) in patients (pts) with BRAF V600E mt mCRC and 43% (3/7) in pts with other cancers. The overall clinical benefit rate (partial response + stable disease) was 71% (27/38). Here we report the utility of ctDNA as a biomarker to predict outcomes and understand mechanisms of treatment resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
